The leading Australian CRO for biotechs, Avance Clinical, hosted a visit with the Premier of South Australia the Hon. Steven Marshall MP to discuss the fast-growing clinical trials sector, currently worth $50 billion and increasing to $71.7 billion by 2024 according to Frost & Sullivan.
As oncology sponsors look internationally to speed-up trials after unprecedented COVID-19 suspensions and delays, Australia, which has led the world in minimizing the pandemic’s impact, stands out as an attractive destination for early phase trials. This in combination with the streamlined regulatory system and the financial benefits including a very favourable exchange rate and the R & D cash rebate makes Australia the perfect location for accelerating biotech clinical programs.
A joint BiospectrumAsia and Avance Clinical special webinar featuring Gabriel KremmidiotisPhD, BSC Hon, Chief Scientific Officer Avance Clinical. Registration is now open CLICK HERE
Avance Clinical, which has been offering CRO services for more than two decades for early phase trials, reports 95 new trials were registered in the past 30 days as recorded in Australian and New Zealand registry ANZCTR.org.au Read the news article here
Adelaide, Australia – Leading Australian CRO Avance Clinical said there was still strong demand from Asian and US sponsors, and commended Australian sites that had risen to the challenge to deliver for Avance Clinical clients during this difficult time. Avance Clinical is a medium-sized full-service CRO known for its nimble and collaborative approach, with […]
Leading Australian CRO Avance Clinical today detailed the top reasons its APAC biotechs selected Australia for their early phase clinical trials, based on client onboarding feedback. Avance Clinical is a specialist Australian CRO with more than 20-years of early phase clinical trials expertise. Avance Clinical said a primary reason that APAC biotechs chose Australia was […]
